Clinical and Translational Radiation Oncology (Nov 2022)
PEARLS – A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA‐avid pelvic and/or para-aortic lymph nodes at presentation
- Julia Murray,
- Clare Cruickshank,
- Thomas Bird,
- Philip Bell,
- John Braun,
- Dave Chuter,
- Miguel Reis Ferreira,
- Clare Griffin,
- Shama Hassan,
- Nabil Hujairi,
- Alan Melcher,
- Elizabeth Miles,
- Olivia Naismith,
- Miguel Panades,
- Lara Philipps,
- Alison Reid,
- Jan Rekowski,
- Pete Sankey,
- John Staffurth,
- Isabel Syndikus,
- Alison Tree,
- Anna Wilkins,
- Emma Hall
Affiliations
- Julia Murray
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK; Corresponding author at: The Royal Marsden NHS Trust, London, UK.
- Clare Cruickshank
- The Institute of Cancer Research, London, UK
- Thomas Bird
- University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, UK
- Philip Bell
- NCRI Consumer Forum, London, UK
- John Braun
- RMH Radiotherapy Focus Group & RMH Biomedical Research Centre Consumer Group, Sutton, UK
- Dave Chuter
- NCRI Consumer Forum, London, UK; NCRI Living With & Beyond Cancer (Acute and Toxicities Workstream), London, UK
- Miguel Reis Ferreira
- Guys & St Thomas NHS Trust and King’s College, London, UK
- Clare Griffin
- The Institute of Cancer Research, London, UK
- Shama Hassan
- The Institute of Cancer Research, London, UK
- Nabil Hujairi
- The Royal Marsden NHS Foundation Trust, London, UK
- Alan Melcher
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
- Elizabeth Miles
- Radiotherapy Trials QA Group (RTTQA), Mount Vernon Hospital, Northwood, UK
- Olivia Naismith
- Radiotherapy Trials QA Group (RTTQA), Royal Marsden NHS Foundation Trust, London, UK
- Miguel Panades
- United Lincolnshire Hospitals NHS Trust, Lincoln, UK
- Lara Philipps
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
- Alison Reid
- The Royal Marsden NHS Foundation Trust, London, UK
- Jan Rekowski
- The Institute of Cancer Research, London, UK
- Pete Sankey
- University Hospitals Plymouth NHS Trust, Plymouth, UK
- John Staffurth
- Velindre University NHS Trust and Cardiff University, Cardiff, UK
- Isabel Syndikus
- Clatterbridge Cancer Centre, Wirral, UK
- Alison Tree
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
- Anna Wilkins
- The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
- Emma Hall
- The Institute of Cancer Research, London, UK
- Journal volume & issue
-
Vol. 37
pp. 130 – 136
Abstract
PEARLS is a multi-stage randomised controlled trial for prostate cancer patients with pelvic and/or para-aortic PSMA-avid lymph node disease at presentation. The aim of the trial is to determine whether extending the radiotherapy field to cover the para-aortic lymph nodes (up to L1/L2 vertebral interspace) can improve outcomes for this patient group.
